Literature DB >> 29298420

The Apolipoprotein M/S1P Axis Controls Triglyceride Metabolism and Brown Fat Activity.

Christina Christoffersen1, Christine K Federspiel2, Anna Borup3, Pernille M Christensen2, Andreas N Madsen4, Markus Heine5, Carsten H Nielsen6, Andreas Kjaer6, Birgitte Holst4, Joerg Heeren5, Lars B Nielsen7.   

Abstract

Apolipoprotein M (apoM) is the carrier of sphingosine-1-phosphate (S1P) in plasma high-density lipoproteins. S1P is a bioactive lipid interacting with five receptors (S1P1-5). We show that lack of apoM in mice increases the amount of brown adipose tissue (BAT), accelerates the clearance of postprandial triglycerides, and protects against diet-induced obesity (i.e., a phenotype similar to that induced by cold exposure or β3-adrenergic stimulation). Moreover, the data suggest that the phenotype of apoM-deficient mice is S1P dependent and reflects diminished S1P1 stimulation. The results reveal a link between the apoM/S1P axis and energy metabolism.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  apoM; apolipoproteins; brown adipose tissue; lipid metabolism; lipoproteins; sphingolipids; sphingosine-1-phosphate; triglyceride

Mesh:

Substances:

Year:  2018        PMID: 29298420     DOI: 10.1016/j.celrep.2017.12.029

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  23 in total

1.  Editorial on Sramkova et al., "Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction".

Authors:  Chih-Wei Ko; Jie Qu; Patrick Tso
Journal:  Am J Clin Nutr       Date:  2019-06-01       Impact factor: 7.045

2.  Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice.

Authors:  Hideru Obinata; Andrew Kuo; Yukata Wada; Steven Swendeman; Catherine H Liu; Victoria A Blaho; Rieko Nagumo; Kenichi Satoh; Takashi Izumi; Timothy Hla
Journal:  J Lipid Res       Date:  2019-08-28       Impact factor: 5.922

Review 3.  Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases.

Authors:  Nathalie Burg; Jane E Salmon; Timothy Hla
Journal:  Nat Rev Rheumatol       Date:  2022-05-04       Impact factor: 20.543

4.  Sphingolipids in Adipose: Kin or Foe?

Authors:  Yolander Valentine; L Ashley Cowart
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 5.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Insulin Resistance in Apolipoprotein M Knockout Mice is Mediated by the Protein Kinase Akt Signaling Pathway.

Authors:  Shuang Yao; Jun Zhang; Yuxia Zhan; Yuanping Shi; Yang Yu; Lu Zheng; Ning Xu; Guanghua Luo
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

Review 7.  Novel insights into the pathological mechanisms of metabolic related dyslipidemia.

Authors:  Xin Su; Ye Cheng; Guoming Zhang; Bin Wang
Journal:  Mol Biol Rep       Date:  2021-07-04       Impact factor: 2.316

Review 8.  Apolipoprotein M-A Marker or an Active Player in Type II Diabetes?

Authors:  Christina Christoffersen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-21       Impact factor: 5.555

Review 9.  Sphingolipids in metabolic disease: The good, the bad, and the unknown.

Authors:  Christopher D Green; Michael Maceyka; L Ashley Cowart; Sarah Spiegel
Journal:  Cell Metab       Date:  2021-07-06       Impact factor: 31.373

10.  Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk.

Authors:  Yitian Zhou; Reedik Mägi; Lili Milani; Volker M Lauschke
Journal:  J Lipid Res       Date:  2018-08-03       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.